INDIMIX
LIVE

Serial Number

79350511

Owner

INDICAL BIOSCIENCE GmbH

Attorney

Leo M. Loughlin

Filing Date

Jun 21, 2022

Add to watchlist:

No watchlists yet
View on USPTO

INDIMIX Trademark

Serial Number: 79350511 • Registration: 7646253

INDIMIX is a trademark filed by INDICAL BIOSCIENCE GmbH on June 21, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

INDICAL BIOSCIENCE GmbH (7 trademarks)

Deutscher Platz 5b

Entity Type: 27

Trademark Details

Filing Date

June 21, 2022

Registration Date

January 14, 2025

Published for Opposition

September 17, 2024

Goods & Services

Pharmaceutical medical preparations for treating infections; veterinary medical products, namely, vaccines; medical products for medical healthcare purposes, namely, reagents for medical use; diagnostic preparations for medical and veterinary purposes; diagnostic agents for medical and veterinary purposes, namely, diagnostic agents for medical and veterinary in-vitro diagnostics; diagnostic agents for medical and veterinary purposes, namely, biological diagnostic agents for testing diseases in cattle, pigs, and other animals; kits comprised of reagents for medical use, of antisense oligonucleotides being pharmaceutical preparations of monoclonal antibodies for use in disease testing, and of in-vitro diagnostic reagents and diagnostic control reagents all for medical purposes, sold as a unit for medical purposes; diagnostic test kits comprised of testing equipment in the nature of biomolecules, namely, antisense oligonucleotides being pharmaceutical preparations, primers in the nature of nucleic acid sequences and probes in the nature of single stranded sequences for DNA and RNA biomarker testing and DNA and RNA infectious disease testing for medical, veterinary, and dental purposes; products for medical and veterinary medical purposes, namely, diagnostic preparations for sample preparation, for modification and manipulation of cells and for labelling, for separation, for isolation, for purification, for amplification and for analysis of natural and synthetic biopolymers, in the nature of nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances all being diagnostic medical preparations; chemical, biochemical and biotechnological products, namely, reagents for medical use, for sample preparation, and for modification and manipulation of cells, all for medical use; in vitro diagnostic preparations for medical purposes; diagnostic disease testing kits comprised of medical diagnostic reagents; buffers for medical and veterinary purposes, namely, extraction buffers; diagnostic disease testing kits comprised of chemical reagents for medical use, antisense oligonucleotides being pharmaceutical preparations, nucleotides being pharmaceutical preparations, extraction buffers, in-vitro diagnostic preparations, and diagnostic control reagents, all for medical and veterinary use, sold as a unit for medical and veterinary use

Chemical, biochemical and biotechnological reagents for industrial and scientific purposes and laboratory analysis, other than in vivo use and other than for medical or veterinary purposes; Chemical, biochemical and biotechnological substances for industrial and scientific purposes and laboratory analysis, other than in vivo use and other than for medical or veterinary purposes; Biochemicals for scientific and research use, namely, for sample preparation, modification and manipulation of cells and for labeling, isolation, purification, amplification and analysis of natural and synthetic biopolymers in the nature of nucleotides, buffer substances such as salts and proteins for industrial use, macromolecules and biologically active substances, none of the foregoing for medical or veterinary use; biochemicals, namely, small molecular chemicals for scientific or research use; laboratory chemicals, namely, small molecular chemicals used for the detection of nucleic acids in cell and tissue analysis for in vitro diagnostic use; chemicals and biochemical preparations used in industry, in particular, chemical and biochemical substances for molecular biological, biochemical and immunological laboratory testing and analysis, other than for medical or veterinary purposes; kits comprising biochemical reagents for scientific and research use, namely, for sample preparation, modification and manipulation of samples and cells and for labeling, separation, isolation, purification, especially amplification and analysis of natural and synthetic biopolymers, in particular, nucleic acids for laboratory use, oligonucleotides, proteins for industrial use, macromolecules and biologically active substances, none of the foregoing for medical or veterinary use; kits for multiplex polymerase chain reaction (PCR) tests comprised of DNA primers for amplifying DNA and RNA loci

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 1, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 11, 2025 FICS
FINAL DISPOSITION PROCESSED
Jul 11, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 14, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 14, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 14, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 17, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 17, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 28, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 9, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 5, 2024 TROA
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 18, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 28, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 28, 2024 OPNR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 9, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 9, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 9, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 6, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 6, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 6, 2023 TROA
REFUSAL PROCESSED BY IB
Jun 26, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 6, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jun 6, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 9, 2023 RFCR
NON-FINAL ACTION WRITTEN
Apr 8, 2023 CNRT
ASSIGNED TO EXAMINER
Apr 1, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 27, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 23, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 22, 2022 REPR